Law360 (October 23, 2006, 12:00 AM EDT) -- Inspire Pharmaceuticals Inc. disclosed Monday that it may face charges from the Securities and Exchange Commission over a Phase 3 clinical trial for its dry-eye product candidate, Prolacria.
The Durham, N.C.-based...
SEC Threatens Inspire With Civil Action
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
